- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Tharimmune, Inc.: Tharimmune To Participate in Two Upcoming Investor Conferences in May | 101 | ACCESSWIRE | BRIDGEWATER, NJ / ACCESSWIRE / April 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates... ► Artikel lesen | |
| 23.04. | Tharimmune Announces Option for Novel HER2/HER3 Cancer Therapies | 2 | Contract Pharma | ||
| 23.04. | Tharimmune, Inc.: Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates | 168 | ACCESSWIRE | Obtained rights from Washington University to develop and incorporate human HER2 directed antibodiesComplements early pipeline of novel tunable "Knob domain" antibodies for HER2 & HER3 BRIDGEWATER,... ► Artikel lesen | |
| 15.04. | Tharimmune, Inc.: Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics | 164 | ACCESSWIRE | Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovationBRIDGEWATER, NJ / ACCESSWIRE / April... ► Artikel lesen | |
| 01.04. | Mahindra To Unveil 5-Door Thar On August 15! | - | The Free Press Journal | ||
| 27.03. | Force Teases 5-Door Gurkha SUV, Competing Head-on With Mahindra Thar | 1 | The Free Press Journal | ||
| 11.03. | Tharimmune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.03. | Tharimmune, Inc.: Tharimmune to Present at the Emerging Growth Conference on March 7, 2024 | 194 | ACCESSWIRE | Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth ConferenceBRIDGEWATER, NJ / ACCESSWIRE... ► Artikel lesen | |
| 28.02. | Through Dust And Dirt: Mahindra Brings The New Thar 'Earth Edition' | 1 | The Free Press Journal | ||
| 27.02. | Mahindra introduces Thar Earth Edition: Check variant-wise price, features | 2 | ZEE Business | ||
| 23.02. | Tharimmune, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 20.02. | Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease | 1 | Benzinga.com | ||
| 20.02. | Tharimmune reports successful phase 1 trial for pruritus drug TH104 | 1 | Investing.com | ||
| 20.02. | Tharimmune, Inc.: Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate | 530 | ACCESSWIRE | Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studiesPhase 1 clinical trial compared oral transmucosal delivery of TH104... ► Artikel lesen | |
| 13.02. | Thar be safe harbor: Reddit defeats third attempt to unmask digital pirates | 1 | The Register | ||
| 05.02. | Tharimmune, Inc.: Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis | 236 | ACCESSWIRE | Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104Phase 1 study expected to be completed in 1Q24 with topline... ► Artikel lesen | |
| 29.01. | Tharimmune, Inc.: Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update | 410 | ACCESSWIRE | Phase 1 trial initiated to assess safety/tolerability and absolute bioavailability of TH104 with topline data expected in 2Q24Planning well underway for Phase 2 of TH104 in primary biliary cholangitis... ► Artikel lesen | |
| 30.12.23 | Maruti Suzuki Jimny vs Mahindra Thar - A comprehensive comparison | 5 | ZEE Business | ||
| 19.12.23 | Mahindra & Mahindra to add Vision Thar.e Electric SUV to its lineup in 2024 | 4 | ZEE Business | ||
| 07.12.23 | Tharimmune, Inc. - 8-K, Current Report | 3 | SEC Filings |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CELLECTAR BIOSCIENCES | 3,140 | +8,28 % | Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update | FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 9,700 | +7,18 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 | Data to be presented will highlight latest preclinical safety data for PBGENE-HBV in preparation for regulatory filings in 2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing... ► Artikel lesen | |
| Q32 BIO | 25,300 | -2,32 % | Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer | WALTHAM, Mass., April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis... ► Artikel lesen | |
| ROIVANT SCIENCES | 10,350 | +1,37 % | Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis | Namilumab is a fully human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine believed to play a key role in the pathogenesis... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,840 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| MORPHOSYS | 65,75 | -0,68 % | Flut an Quartalszahlen: So reagiert der DAX - Außerdem im Fokus: Adidas und MorphoSys | Am Dienstag sind eine ganze Fülle von wichtigen Quartalszahlen präsentiert worden. Wie reagiert der deutsche Leitindex darauf? Außerdem im Fokus: Adidas und MorphoSys. Die Anleger am deutschen Aktienmarkt... ► Artikel lesen | |
| EVOTEC | 10,040 | +3,08 % | Evotec: Management optimistisch - Umsatz-Milliarde im Blick | Ist heute schon der Auftakt einer großen Gegenbewegung? Nach einem Verlust der Evotec-Aktie (WKN: 566480) von zeitweise mehr als 40% am gestrigen Tage dürfte der Markt zunehmend zur Besinnung kommen.... ► Artikel lesen | |
| ARVINAS | 32,480 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| QIAGEN | 39,880 | +2,05 % | QIAGEN N.V.: QIAGEN übertrifft Prognosen für das erste Quartal 2024 und bleibt auf Kurs, die Jahresziele 2024 zu erreichen | Q1 2024: Konzernumsatz von $459 Mio. (-5% bei tatsächlichen Kursen; -5% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,36; bereinigter verwässerter Gewinn je Aktie von $0,46... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,740 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,310 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| COGENT BIOSCIENCES | 6,910 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor | WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 28,100 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 4,206 | +174,54 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
| NUVALENT | 70,65 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |
Das Unternehmen THARIMMUNE INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
